Thus, candidates should be tested against a panel of receptors at the time of antibody engineering. ACROBiosystems provides an extensive collection of recombinant Fc receptor proteins, which ...

Previous studies established defective Fc receptor mediated clearance in patients with systemic lupus erythematosis (SLE), a disorder associated with circulating immune complexes (CIC).

The binding between a biosimilar and its target antigen (and Fc receptors) is regarded as a key indicator of its efficacy. ACROBiosystems has designed high-quality target antigen proteins and Fc ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, its investigational neonatal Fc receptor (FcRn) blocker, in generalized ...